Company Filing History:
1 out of 2 
1 out of 12 Years Active: 2012
Title: Guenter Waxenecker: Innovator in Monoclonal Antibody Development
Introduction
Guenter Waxenecker is a notable inventor based in Mank, Austria. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of monoclonal antibodies. His innovative work has the potential to impact cancer treatment significantly.
Latest Patents
Guenter Waxenecker holds a patent for a method of treating Lewis Y-expressing tumors. This invention relates to a monoclonal antibody or a derivative or fragment thereof that recognizes the Lewis Y antigen. The patent is characterized by an Fc region that carries a bi-sected hybrid type N-glycosylation pattern. This antibody demonstrates at least a tenfold increase in antibody-dependent cellular cytotoxicity (ADCC) and at least a 10% reduction in complement-dependent cytotoxicity (CDC) activity. He has 1 patent to his name.
Career Highlights
Throughout his career, Guenter has worked with various companies in the biopharmaceutical sector. Notably, he has been associated with Meridian Biopharmaceuticals GmbH and Greenovation Biotech GmbH. His work in these organizations has contributed to advancements in therapeutic solutions.
Collaborations
Guenter has collaborated with several professionals in his field, including Manfred Schuster and Gottfried Himmler. These collaborations have fostered innovation and development in monoclonal antibody research.
Conclusion
Guenter Waxenecker is a prominent figure in the biopharmaceutical industry, known for his innovative work on monoclonal antibodies. His contributions, particularly in treating Lewis Y-expressing tumors, highlight the importance of research and development in advancing medical treatments.